These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 24847017)

  • 21. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesh-covered embolic protection stent implantation in ST-segment-elevation myocardial infarction: final 1-year clinical and angiographic results from the MGUARD for acute ST elevation reperfusion trial.
    Dudek D; Dziewierz A; Brener SJ; Abizaid A; Merkely B; Costa RA; Bar E; Rakowski T; Kornowski R; Dressler O; Abizaid A; Silber S; Stone GW
    Circ Cardiovasc Interv; 2015 Feb; 8(2):e001484. PubMed ID: 25603802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
    Wykrzykowska J; Serruys P; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; Di Mario C; Van Geuns RJ; Van Es GA; Juni P; Windecker S
    EuroIntervention; 2011 Nov; 7(7):789-95. PubMed ID: 22027687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
    Klauss V; Serruys PW; Pilgrim T; Buszman P; Linke A; Ischinger T; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; van Es GA; Kalesan B; Wenaweser P; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2011 Aug; 4(8):887-95. PubMed ID: 21851904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
    De Luca G; Sauro R; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Palmieri V; Serino V; Rosato G; Suryapranata H; Di Lorenzo E
    Diab Vasc Dis Res; 2015 Sep; 12(5):306-14. PubMed ID: 26150193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
    Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F
    Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thin Strut CoCr Biodegradable Polymer Biolimus A9-Eluting Stents versus Thicker Strut Stainless Steel Biodegradable Polymer Biolimus A9-Eluting Stents: Two-Year Clinical Outcomes.
    Menown IBA; Mamas MA; Cotton JM; Hildick-Smith D; Eberli FR; Leibundgut G; Tresukosol D; Macaya C; Copt S; Slama SS; Oldroyd KG
    J Interv Cardiol; 2021; 2021():6654515. PubMed ID: 33880087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Impact of Intravascular Ultrasound-Guided Chronic Total Occlusion Intervention With Zotarolimus-Eluting Versus Biolimus-Eluting Stent Implantation: Randomized Study.
    Kim BK; Shin DH; Hong MK; Park HS; Rha SW; Mintz GS; Kim JS; Kim JS; Lee SJ; Kim HY; Hong BK; Kang WC; Choi JH; Jang Y;
    Circ Cardiovasc Interv; 2015 Jul; 8(7):e002592. PubMed ID: 26156151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five-Year Optical Coherence Tomography in Patients With ST-Segment-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents.
    Gomez-Lara J; Brugaletta S; Jacobi F; Ortega-Paz L; Ñato M; Roura G; Romaguera R; Ferreiro JL; Teruel L; Gracida M; Martin-Yuste V; Freixa X; Masotti M; Gomez-Hospital JA; Sabate M; Cequier A
    Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27702766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
    Holmvang L; Kelbæk H; Kaltoft A; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
    JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
    Am Heart J; 2009 Oct; 158(4):e43-50. PubMed ID: 19781402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term coronary arterial response to biodegradable polymer biolimus-eluting stents in comparison with durable polymer sirolimus-eluting stents and bare-metal stents: five-year follow-up optical coherence tomography study.
    Kuramitsu S; Sonoda S; Yokoi H; Iwabuchi M; Nishizaki Y; Shinozaki T; Domei T; Hyodo M; Inoue K; Shirai S; Ando K; Nobuyoshi M
    Atherosclerosis; 2014 Nov; 237(1):23-9. PubMed ID: 25190308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial.
    Stone SG; Serrao GW; Mehran R; Tomey MI; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Möckel M; Brener SJ; Dangas G; Stone GW
    Circ Cardiovasc Interv; 2014 Aug; 7(4):543-51. PubMed ID: 24939928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiographic and clinical performance of polymer-free biolimus-eluting stent in patients with ST-segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study.
    Sgueglia GA; D'Errico F; Gioffrè G; De Santis A; Summaria F; Piccioni F; Gaspardone A
    Catheter Cardiovasc Interv; 2018 Apr; 91(5):851-858. PubMed ID: 28766881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex-related Impact on Clinical Outcome of Everolimus-eluting Versus Bare-metal Stents in ST-segment Myocardial Infarction. Insights From the EXAMINATION Trial.
    Regueiro A; Fernández-Rodríguez D; Brugaletta S; Martín-Yuste V; Masotti M; Freixa X; Cequier Á; Íñiguez A; Serruys PW; Sabaté M;
    Rev Esp Cardiol (Engl Ed); 2015 May; 68(5):382-9. PubMed ID: 25444377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction.
    Zhang YJ; Iqbal J; Windecker S; Linke A; Antoni D; Sohn HY; Corti R; van Es GA; Copt S; Eerdmans P; Saitta R; Morice MC; Di Mario C; Juni P; Wijns W; Buszman P; Serruys PW
    Heart; 2015 Feb; 101(4):271-8. PubMed ID: 25423953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-year clinical outcomes of the NOBORI biolimus-eluting stents versus XIENCE/PROMUS everolimus-eluting stents in small vessel disease.
    Jinnouchi H; Kuramitsu S; Shinozaki T; Hiromasa T; Kobayashi Y; Morinaga T; Yamaji K; Soga Y; Shirai S; Ando K
    Catheter Cardiovasc Interv; 2016 Nov; 88(5):E132-E138. PubMed ID: 26708085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
    Christiansen EH; Jensen LO; Thayssen P; Tilsted HH; Krusell LR; Hansen KN; Kaltoft A; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Villadsen AB; Ravkilde J; Aarøe J; Madsen M; Thuesen L; Lassen JF;
    Lancet; 2013 Feb; 381(9867):661-9. PubMed ID: 23374649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.
    Massberg S; Byrne RA; Kastrati A; Schulz S; Pache J; Hausleiter J; Ibrahim T; Fusaro M; Ott I; Schömig A; Laugwitz KL; Mehilli J;
    Circulation; 2011 Aug; 124(5):624-32. PubMed ID: 21768546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.